SCHEMBL1621426

SCHEMBL1621426

CC(C)(C)S(=O)(=O)C(C)(C)C(=O)Nc1cccc(C(F)(F)F)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RORC P51449 1/20 0.49
▸ GSK3A P49840 6/20 0.47
▸ GSK3B P49841 6/20 0.47
▸ SRPK1 Q96SB4 4/20 0.47
▸ AURKA O14965 1/20 0.47
▸ PRKX P51817 1/20 0.47
▸ PRKG1 Q13976 1/20 0.47
▸ MAPKAPK5 Q8IW41 1/20 0.47
▸ TAS2R14 Q9NYV8 1/20 0.47
▸ P2RX7 Q99572 1/20 0.43
▸ GRM5 P41594 2/20 0.43
▸ CLK4 Q9HAZ1 10/20 0.42
▸ ACVR1 Q04771 9/20 0.42
▸ HIPK4 Q8NE63 5/20 0.42
▸ STK3 Q13188 4/20 0.42
▸ AURKB Q96GD4 4/20 0.42
▸ CDK8 P49336 4/20 0.42
▸ FLT3 P36888 3/20 0.42
▸ CSNK2A1 P68400 3/20 0.42
▸ PRKD3 O94806 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1464507 0.85 TAS2R14 (0.52) RORCGSK3AGSK3BSRPK1AURKA
SCHEMBL1621558 0.84 RORC (0.53) RORCGSK3AGSK3BSRPK1AURKA
SCHEMBL3656731 0.82 RORC (0.51) RORCGSK3AGSK3BSRPK1AURKA
SCHEMBL1464871 0.82 CNR2 (0.55) RORCGSK3AGSK3BSRPK1AURKA
SCHEMBL1464360 0.82 CNR2 (0.50) RORCGSK3AGSK3BSRPK1AURKA
SCHEMBL1464304 0.82 CNR2 (0.50) RORCGSK3AGSK3BSRPK1AURKA
SCHEMBL1621561 0.82 RORC (0.51) RORCGSK3AGSK3BSRPK1AURKA
SCHEMBL1464316 0.81 GSK3A (0.49) RORCGSK3AGSK3BSRPK1AURKA
SCHEMBL1464461 0.81 CNR2 (0.49) RORCGSK3AGSK3BSRPK1AURKA
SCHEMBL1621429 0.81 RORC (0.48) RORCGSK3AGSK3BSRPK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074084-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-08-28 — — EP claimed
US-7928123-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-19 — — US claimed
US-20080081822-A1 N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-04-03 — — US claimed
US-8829034-B2 Compounds which modulate the CB2 receptor Boehringer Ingerlheim International GmbH (DE) 2014-09-09 — — US disclosed
US-8829034-B2 Compounds which modulate the CB2 receptor Boehringer Ingerlheim International GmbH (DE) 2014-09-09 — — US disclosed
EP-2074084-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-08-28 — — EP disclosed
EP-2074084-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-08-28 — — EP disclosed
US-20110130431-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-06-02 — — US disclosed
US-7928123-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-19 — — US disclosed
US-7928123-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-04-19 — — US disclosed
US-20080081822-A1 N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-04-03 — — US disclosed
US-20080081822-A1 N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-04-03 — — US disclosed
WO-2008039645-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080081822-A1 N-(5-tert-Butyl-isoxazol-3-yl)-2-cyclohexanesulfonyl-2-methyl-propionamide; cannabinoid receptor agonist, antagonist; analgesic, antiinflammatory and antitumor agent; neuropatic pain CNR2, CNR1, OPRL1 RORC 509/4885GSK3A 3446/4885GSK3B 3690/4885
US-20110130431-A1 Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 RORC 273/4885GSK3A 2084/4885GSK3B 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback